Patents by Inventor Phi Wiegn

Phi Wiegn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for increasing vascular density and maintaining viability of microvascular endothelial cells using trk receptor ligands
    Patent number: 8853163
    Abstract: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: October 7, 2014
    Assignees: Cornell Research Foundation, Inc., Children's Medical Center Corporation
    Inventors: Barbara L. Hempstead, Rosemary Kraemer, Shahin Rafii, Phi Wiegn, Michael J. Donovan
  • METHODS FOR REGULATING ANGIOGENESIS AND VASCULAR INTEGRITY USING TRK RECEPTOR LIGANDS
    Publication number: 20100227823
    Abstract: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
    Type: Application
    Filed: May 21, 2010
    Publication date: September 9, 2010
    Applicants: CORNELL RESEARCH FOUNDATION, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barbara L. HEMPSTEAD, Rosemary KRAEMER, Shahin RAFII, Phi WIEGN, Michael J. DONOVAN
  • Methods for increasing capillary density and maintaining viability of microvascular cardiac endothelial cells using trk receptor ligands
    Patent number: 7723293
    Abstract: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: May 25, 2010
    Assignees: Cornell Research Foundation, Inc., Children's Medical Center Corporation
    Inventors: Barbara L. Hempstead, Rosemary Kraemer, Shahin Rafii, Phi Wiegn, Michael L. Donovan
  • Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
    Publication number: 20070110735
    Abstract: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.
    Type: Application
    Filed: October 30, 2006
    Publication date: May 17, 2007
    Applicants: Cornell Research Foundation, Inc., Children's Medical Center Corporation
    Inventors: Barbara Hempstead, Rosemary Kraemer, Shahin Rafii, Phi Wiegn, Michael Donovan
  • Enzymatic fluorometric assay for adenylate cyclase
    Patent number: 5618665
    Abstract: A method for measuring the amount of adenylate cyclase without the use of radioactive reagents is provided. The method comprises combining a sample of physiological material containing an amount of cAMP with (a) a mixture of enzymes effective to eliminate any other endogenous adenine nucleotides which may be present in the sample; and (b) an amount of alkaline phosphatase effective to eliminate any glucose-6-phosphate present in the sample. The cAMP present in said sample is then converted to AMP and the amount of AMP measured, which may then be correlated to the amount of cAMP and AC present in the sample.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: April 8, 1997
    Assignee: Regents of the University of Minnesota
    Inventors: Keith G. Lurie, Phi Wiegn, Atsushi Sugiyama
  • Enzymatic fluorometric assay for adenylate cyclase
    Patent number: 5316907
    Abstract: A method of measuring adenylate cyclase (AC) in a sample of physiological material which does not employ radioactive reagents is provided, comprising:(a) providing a physiological sample of physiological material comprising cAMP produced by endogenous AC, and other endogenous adenine nucleotides selected from the group consisting of ATP, AMP, ADP and mixtures thereof;(b) combining the sample with effective amounts of apyrase, 5'-nucleotidase and adenosine deaminase, so as to enzymatically eliminate the other endogenous adenine nucleotides in the sample;(c) enzymatically converting the cAMP into AMP; and(d) measuring the amount of AMP, the amount providing a measure of the amount of cAMP and AC in the sample.
    Type: Grant
    Filed: January 22, 1993
    Date of Patent: May 31, 1994
    Assignee: Regents of the University of Minnesota
    Inventors: Keith G. Lurie, Phi Wiegn